-
Cgas sting pathway deep · HT(Page)
PD-1 Blockade in B-Cell Lymphomas: A Comprehensive Overview(Post)
Understanding PD-1 Blockade in B-Cell Lymphomas Understanding PD-1 Blockade in B-Cell Lymphomas Introduction The programmed cell death prote
Macrophage Phagocytosis & the CD47–SIRPα Checkpoint(Page) PharmaGenie ELISA Kits(Page)PharmaGenie ELISA Kits | ISO-Validated BioPharma ELISA | Assay Genie
TIGIT/DNAM-1/CD155 (PVR) Checkpoint Axis(Page) Ladiratuzumab Vedotin: Targeting TNBC with Next-Gen ADC Therapy(Post)Quick Facts About Ladiratuzumab VedotinWhat is Ladiratuzumab Vedotin?Ladiratuzumab Vedotin is an antibody-drug conjugate (ADC) designed to target LIV-1, a protein commonly expressed in t
Car t signalling pathway · H(Page) Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Bcell germinal centre pathway(Page) Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
mRNA-1010 and Beyond: How Moderna's mRNA Platform is Revolutionizing Hantavirus Vaccine Development(Post)Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines
Inebilizumab: Advancing Research and Clinical Applications(Post)What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas
NF-κB Signalling Pathway(Page) Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Mast Cells IgE and Type 2 Immunity(Page) Fezakinumab: Exploring Its Mechanism and Clinical Potential(Post)Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
Cytokine JAK/STAT signalling(Page) Infectious Disease ELISA(Page)Infectious Disease ELISA Kits | Viral, Bacterial & Fungal
Citations(Page) Apoptosis Pathway: Death Receptor, Mitochondrial and Granzyme Routes(Post)Apoptosis is not one pathway but three routes into the same execution machinery. A death ligand at the surface, a mitochondrion that loses outer-membrane integrity, and a granzyme delivered by a cyto
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
Key Players in T Cell Regulation: Lag-3, Tim-3, and TIGIT(Post)Understanding Lag-3, Tim-3, and TIGIT: Key Players in T Cell RegulationThe immune system's ability to regulate T cell responses is crucial for maintaining homeostasis and combating diseases such as ca
Fc Receptors Explained: ADCC, ADCP, CDC and the CD32B Brake(Post)An antibody's variable domains decide what it binds. Its Fc decides what happens next — and that is not a detail of formulation, it is half the mechanism. Which Fcγ receptor the constant region engag
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
PD-1 PD-L1 Pathway Diagram(Page) cGAS-STING cytosolic DNA sensing(Page) Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
Regulatory T Cells and the IL-2 Paradox(Page) Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Mucosal Homing and Tissue-Resident Memory(Page) Nfkb signalling pathway · HTM(Page) Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
Th17 Cells and the IL-23 Axis(Page) Neutrophil Activation & NETosis(Page) Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
TNF Receptor Superfamily: TNFR1 vs TNFR2(Page) Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Adenosine Axis — CD39, CD73 and A2A Receptors(Page) Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
Two Asthma Drugs, Opposite Eosinophil Counts, Both Working(Post)Two asthma biologics have opposite effects on the blood eosinophil count, and both of them work. Mepolizumab empties the eosinophil compartment; dupilumab can transiently raise it. If that seems cont
No Ligand, No Kinase, No Problem(Post)HER2 has no ligand. HER3 has no kinase. Together they are the most potent signalling pair in human biology. That single sentence explains most of what is strange about this receptor family and all of
Tgf beta smad pathway · HT(Page) The NLRP3 inflammasome & pyroptosis(Page) Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Canine Multiplex ELISA Panels(Page)Canine Multiplex ELISA & Cytokine Assay Panels | Assay Genie
TGF-β/SMAD signalling(Page) Narsoplimab: Targeting MASP-2 to Advance Therapies in Immune-Mediated Disorders(Post)Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the m
In Vivo depletion atlas(Page) Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Erenumab: Transforming Migraine Prevention Through CGRP Receptor Inhibition(Post)Quick Facts About ErenumabWhat is Erenumab?Erenumab is a fully human monoclonal antibody designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor.
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Rat Multiplex ELISA Panels(Page)Rat Multiplex ELISA & Cytokine Assay Panels | Assay Genie
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
The Environmental Shift: How Climate Change and Biodiversity Loss are Driving the Hantavirus Surge(Post)The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public healt
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
IgA Test – Normal Ranges, Results & What They Mean(Post)Clinical · Immunology Guide IgA Test: Normal Ranges, Results & What They Mean [2026] What the immunoglobulin A blood test measures, how result
Combien coûte réellement un anticorps de recherche ?(Post)Combien coûte réellement un anticorps de recherche ? Prévoyez un budget de 130 à 2 500 dollars par anticorps selon le format et l’application visée, mais ce chiffre ne raconte qu’une partie de l’hist
One Integrin Chain, Two Partners, Brain or Gut(Post)A chemokine gradient does not move a leukocyte anywhere. It only tells one that has already stopped which way to go. That sentence is the whole map. Trafficking is a four-step cascade and the steps a
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research(Post)Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research(Post)Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Types of ELISA: Direct, Indirect, Sandwich & Competitive Compared(Post)Written by Seán Mac Fhearraigh, PhD • Updated: 19 May 2026 • ~9 min read Quick Answer The five main types of ELISA are sandwich, competitive, direct, indirect and multiplex. Sandwich ELISA is
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research(Post)Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
LAG-3: Key Regulator of T Cell Immunity(Post)Exploring LAG-3: A Key Regulator in T Cell ImmunityLAG-3 (Lymphocyte Activation Gene-3) is an inhibitory receptor that plays a crucial role in modulating T cell activation and effector functions. This
Multiplex ELISA Protocol(Page) ELISpot Assay Kits(Page)